STAG2 and myeloproliferative neoplasm: Out of 23 cases, 17 patients (73%) had a STAG2 mutation that was detected prior to AML diagnosis, of which 13 patients (76%) were diagnosed with MDS, and 4 patients (24%) with MDS/MPN.